Significant benefit seen with obinutuzumab in lupus nephritis trial
WEB11 hours ago · Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis. Obinutuzumab, a monoclonal antibody that targets the CD20 receptor on B-cells, is ...
UPDATE: Positive Phase III Clinical Trial Results Announced for …
WEB5 days ago · Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized monoclonal antibody designed to attack CD20, a protein found on certain types of B cells that cause inflammation and damage to the kidneys. Gazyva works to deplete disease-causing B cells to protect the kidney from ...
Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial
WEBThe Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva ® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a potential treatment ...
Positive Phase III results for Roche’s Gazyva/Gazyvaro in lupus
WEB1 day ago · “Gazyva/Gazyvaro achieved a robust complete renal response rate in lupus nephritis, which is associated with long-term preservation of kidney function and delay or prevention of end-stage kidney disease,” said Dr Levi Garraway, Roche’s chief medical officer and head of global product development.
Positive Phase III Results for Genentech’s Gazyva Show Superiority …
WEB5 days ago · Lupus nephritis is a potentially life-threatening manifestation of systemic lupus erythematosus, an autoimmune disease that commonly affects the kidneys. Lupus nephritis affects approximately 1.7 ...
How to Manage Lupus Nephritis: A New Guideline Introduced
WEB6 days ago · A new guideline, the 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis, is being introduced at ACR Convergence 2024 on Monday, Nov. 18. In the session, Lisa Sammaritano, MD, professor of clinical medicine at Weill Cornell Medicine and Hospital for Special Surgery, New York, will discuss the guideline development process and...
Researchers Discover Potential New Target for Lupus Nephritis …
WEBApr 17, 2024 · Understanding the immune cells that spur inflammation in lupus nephritis (LN) can help advance knowledge of disease progression and identify new treatments. A new study discovered that macrophages, a type of white blood cells that attack and destroy diseased and damaged cells, may play an important role in …
New Lupus Treatments Offer a Better Chance for Remission
WEBJul 29, 2022 · The good news is that there has been progress, thanks to Food and Drug Administration (FDA) approval in 2021 of two new drugs that treat lupus and lupus nephritis (lupus that involves the kidneys); each has allowed doctors to offer more patients a better chance of remission.
Management of Lupus Nephritis: New Treatments and Updated …
WEBOct 26, 2023 · These new molecular insights into LN provide hope that better and more specific therapies for LN are on the way. Here, we review current standard-of-care (SOC) therapies, newly US Food and Drug Administration (FDA)–approved drugs, and select ongoing clinical trials (Figure. 1).
KDIGO Releases 2024 Lupus Nephritis Guideline - Renal and Urology News
WEBJan 12, 2024 · The Kidney Disease: Improving Global Outcomes (KDIGO) program has published a 2024 clinical practice guideline for the management of lupus nephritis (LN) in Kidney International and its...